Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$19.33 USD

19.33
252,892

+0.49 (2.60%)

Updated Oct 6, 2025 04:00 PM ET

After-Market: $19.35 +0.02 (0.10%) 6:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Amarin (AMRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Zacks Equity Research

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

by Zacks Equity Research

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Zacks Equity Research

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

Zacks Equity Research

Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Zacks Equity Research

Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises

by Zacks Equity Research

AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.

Zacks Equity Research

Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.

Zacks Equity Research

VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales

by Zacks Equity Research

Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.

Zacks Equity Research

Are Medical Stocks Lagging DexCom (DXCM) This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin

by Zacks Equity Research

MAMA, BSET, and AMRN are breakout stocks to watch, each boasting double-digit earnings growth potential in 2025.

Tirthankar Chakraborty headshot

3 Strong Buy Breakout Stocks for Explosive Returns

by Tirthankar Chakraborty

MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

by Abhinab Dasgupta

Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.

Zacks Equity Research

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill

by Zacks Equity Research

MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.

Zacks Equity Research

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

by Zacks Equity Research

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Zacks Equity Research

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

by Zacks Equity Research

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Zacks Equity Research

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?

by Zacks Equity Research

KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

Zacks Equity Research

PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study

by Zacks Equity Research

Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.

Zacks Equity Research

Are Medical Stocks Lagging Amarin (AMRN) This Year?

by Zacks Equity Research

Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.

Zacks Equity Research

Moderna Stock Gains on Encouraging Flu Vaccine Data

by Zacks Equity Research

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Zacks Equity Research

Best Momentum Stock to Buy for June 27th

by Zacks Equity Research

GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.

Zacks Equity Research

Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU

by Zacks Equity Research

AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.

Zacks Equity Research

Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag

by Zacks Equity Research

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.